How to Get Jardiance in Hawaii: Telehealth, Pharmacies, and Prior Authorization

What Is Jardiance and Why Do Hawaii Patients Need It?

Jardiance (empagliflozin) is an SGLT2 inhibitor approved by the FDA for three distinct indications: glycemic control in type 2 diabetes, reduction of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, and reducing the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with CKD. Hawaii has a disproportionately high burden of type 2 diabetes compared with the US national average, with Native Hawaiian and Pacific Islander adults experiencing some of the highest diabetes prevalence rates reported in any US subpopulation. [1]

The EMPA-REG OUTCOME trial (N=7,020) demonstrated that empagliflozin 10 mg or 25 mg daily reduced the rate of death from cardiovascular causes by 38% versus placebo in adults with type 2 diabetes and established cardiovascular disease, with a hazard ratio of 0.62 (95% CI 0.49 to 0.77, P<0.001). [2] That landmark result reframed SGLT2 inhibitors as cardioprotective agents rather than simple glucose-lowering drugs.

The EMPEROR-Reduced trial (N=3,730) showed empagliflozin reduced the primary composite of cardiovascular death or hospitalization for heart failure by 25% versus placebo (HR 0.75 to 95% CI 0.65 to 0.86, P<0.001). [3] Access to this drug matters clinically, not just metabolically.

The FDA label for Jardiance outlines approved dosing, contraindications, and risk mitigation steps that any prescribing clinician in Hawaii must follow before initiating therapy. [4]

Telehealth Prescribing for Jardiance in Hawaii

Hawaii law permits licensed physicians, nurse practitioners, and physician assistants to prescribe Schedule-exempt non-controlled medications via telehealth after a valid patient-provider relationship is established. Empagliflozin is not a controlled substance, so it may be prescribed through a synchronous video visit or, in many cases, an asynchronous evaluation with appropriate documentation of medical history and recent laboratory values.

Hawaii's telehealth parity law requires most commercial insurers to reimburse telehealth visits at the same rate as in-person encounters. [5] That parity covers both the evaluation and, where applicable, the prescription itself.

For patients using HealthRX or a comparable telehealth platform, the typical workflow is:

1. Complete an intake form disclosing current diagnoses, medications, and allergy history.
2. Upload recent labs (eGFR, HbA1c, serum creatinine drawn within the prior 90 days for most platforms, though some accept up to 180 days for stable patients).
3. Attend a synchronous video visit or submit an asynchronous written consult.
4. If clinically appropriate, receive an electronic prescription sent to a Hawaii-licensed pharmacy of your choice.

The American Diabetes Association 2024 Standards of Care recommend SGLT2 inhibitors as preferred add-on therapy for patients with type 2 diabetes and heart failure, atherosclerotic cardiovascular disease, or CKD regardless of baseline HbA1c. [6] That guideline supports initiating empagliflozin via telehealth when laboratory prerequisites are met, because the decision is driven by comorbidity profile, not glycemic threshold alone.

Who Can Prescribe Jardiance in Hawaii?

Any licensed MD, DO, NP (with independent practice authority), or PA practicing in Hawaii may prescribe empagliflozin after a documented clinical evaluation. Hawaii grants full independent practice authority to advanced practice registered nurses (APRNs), including nurse practitioners, without requiring physician oversight. [7] This means NPs practicing on rural Hawaii islands, such as Molokai or Lanai, where physician density is low, can legally initiate and manage Jardiance therapy without a collaborating physician.

Physician assistants in Hawaii must practice under a supervising physician agreement, but that agreement does not prevent a PA from independently writing the prescription if the supervising physician has delegated that authority. The Hawaii Medical Board maintains licensure verification records for all prescribing clinicians. [8]

From a clinical governance standpoint, the prescriber bears responsibility for confirming eGFR is adequate before initiation. The FDA label contraindicates Jardiance in patients with eGFR <20 mL/min/1.73 m2 for CKD indication and generally recommends against initiation when eGFR is <30 mL/min/1.73 m2 for glycemic control. [4]

Required Labs Before Starting Jardiance in Hawaii

Labs are not optional. Getting them drawn before your telehealth visit prevents delays.

The minimum lab panel required by most Hawaii prescribers and telehealth platforms before initiating empagliflozin includes:

• Serum creatinine and eGFR: Confirms kidney function is sufficient for safe prescribing. The CREDENCE trial, which studied canagliflozin but whose eGFR thresholds inform all SGLT2 inhibitor practice, enrolled patients down to eGFR 30 mL/min/1.73 m2. [9] Empagliflozin's FDA label sets specific eGFR floors by indication. [4]
• HbA1c: Documents glycemic status and helps justify the indication for payers during prior authorization.
• Urinalysis: Screens for baseline glycosuria, UTI, or proteinuria before therapy. Because SGLT2 inhibitors increase urinary glucose excretion, a pre-treatment baseline urinalysis simplifies interpretation of post-initiation symptoms.
• Basic metabolic panel: Evaluates sodium, potassium, and bicarbonate, given the small but real risk of euglycemic diabetic ketoacidosis (DKA) with SGLT2 inhibitors, particularly in patients who fast or undergo surgical procedures. [10]

The American Association of Clinical Endocrinology (AACE) 2022 Comprehensive Diabetes Management Algorithm states: "Assessment of kidney function (eGFR) is essential before initiating SGLT2 inhibitor therapy and should be repeated at least annually thereafter." [11]

Quest Diagnostics and LabCorp both operate patient service centers across Honolulu, Hilo, Kailua-Kona, and Kahului. Patients on neighbor islands without local lab access may use mobile phlebotomy services such as Getlabs, which operates in parts of Hawaii.

Hawaii Pharmacies Dispensing Jardiance

Brand-name Jardiance (empagliflozin 10 mg and 25 mg tablets) is available at all major retail pharmacy chains operating in Hawaii, including Longs Drugs (a CVS Health company with 10 Hawaii locations), Safeway Pharmacy, Costco Pharmacy in Honolulu and Maui, and Walmart Pharmacy in Oahu locations.

Mail-order pharmacies such as Express Scripts, CVS Caremark, and Optum Rx ship to all Hawaiian zip codes, including neighbor islands. Standard shipping takes 3 to 5 business days; expedited options can reduce that to 2 business days for most Oahu and Maui addresses.

503A compounding pharmacies licensed in Hawaii may prepare empagliflozin formulations for patients with documented clinical needs that the commercially available tablet strengths do not meet, such as patients requiring dose forms compatible with a feeding tube. A 503A pharmacy operates under individual prescription orders and state pharmacy board oversight, distinct from the federal 503B outsourcing facility category that applies to large-batch production. Hawaii's Board of Pharmacy maintains a public register of state-licensed pharmacies. [12]

Generic empagliflozin is not yet available in the United States. The Jardiance patent estate, managed by Boehringer Ingelheim, is projected to face its first significant patent challenge around 2025 to 2026, but no FDA-approved generic had received final approval as of the publication date of this article.

Prior Authorization for Jardiance in Hawaii

Most commercial health plans in Hawaii require prior authorization (PA) before covering Jardiance. The three largest commercial insurers in Hawaii are Hawaii Medical Service Association (HMSA, the Blue Cross Blue Shield affiliate), Kaiser Permanente Hawaii, and HMAA.

HMSA's formulary places Jardiance on Tier 3 or Tier 4 depending on the specific plan design. Prior authorization criteria typically require documentation of:

1. A confirmed diagnosis of type 2 diabetes, heart failure (HFrEF or HFpEF per the 2022 AHA/ACC Heart Failure Guideline), or CKD with eGFR 20 to 60 mL/min/1.73 m2. [13]
2. A current HbA1c result for diabetes indications.
3. A trial of or contraindication to metformin for the diabetes indication.
4. Prescriber attestation that the patient has an eGFR above the indication-specific floor.

Kaiser Permanente Hawaii uses an integrated formulary and often covers empagliflozin without a separate PA step for members whose medical records already document an eligible diagnosis within the Kaiser system.

The HealthRX Prior Authorization Decision Framework for Hawaii Jardiance requests proceeds in four steps: (1) confirm the indication matches an FDA-approved category; (2) verify eGFR is above the indication-specific threshold using a lab drawn within 90 days; (3) collect documentation of a prior metformin trial or intolerance if the indication is type 2 diabetes; (4) submit the PA request with the prescriber's NPI, the patient's Hawaii plan ID, and the relevant ICD-10 code (E11.65 for type 2 diabetes with hyperglycemia, I50.20 for unspecified heart failure, or N18.30 for CKD stage 3 unspecified).

PA decisions from HMSA typically return within 3 business days for standard review and within 24 hours for urgent clinical circumstances. Denials may be appealed with a letter of medical necessity citing EMPA-REG OUTCOME [2] and the 2024 ADA Standards of Care [6] as guideline support.

Hawaii Medicaid (Med-QUEST) Coverage

Hawaii Medicaid, administered through the Med-QUEST Division, does not currently cover Jardiance for type 2 diabetes, heart failure, or CKD on its preferred drug list as of early 2025. Empagliflozin is not listed as a covered benefit under the standard Med-QUEST formulary for any of its three FDA-approved indications.

Patients enrolled in Med-QUEST managed care plans, such as AlohaCare, HMSA Quest Integration, Kaiser Quest, Molina Healthcare, or UnitedHealthcare Community Plan Hawaii, should verify coverage directly with their plan, because individual managed care contracts occasionally include drugs not on the base preferred drug list. [14]

The CMS-sponsored Medication Access and Patient Safety Act discussions at the federal level may eventually shift state Medicaid programs toward covering SGLT2 inhibitors for CKD given the DAPA-CKD trial (N=4,304) finding that dapagliflozin reduced the risk of a sustained 50% decline in eGFR, end-stage kidney disease, or death from renal or cardiovascular causes by 39% versus placebo (HR 0.61 to 95% CI 0.51 to 0.72, P<0.001). [15] Until federal or state policy changes, however, Med-QUEST patients face an access gap.

The Lilly Cares Foundation offers a patient assistance program for uninsured or underinsured patients. Eligible patients with household income at or below 400% of the federal poverty level may receive Jardiance at no cost. The Boehringer Ingelheim Cares Foundation runs a parallel assistance program. Both require a valid prescription from a licensed Hawaii provider. [16]

How Long Does It Take to Receive Jardiance in Hawaii?

The time from first telehealth visit to having medication in hand depends on three variables: prior authorization processing time, pharmacy dispensing time, and shipping time.

For patients with commercial insurance requiring a PA:

• PA submission to decision: 1 to 3 business days (standard) or 24 hours (urgent).
• Pharmacy processing and dispensing: 1 to 2 business days.
• Shipping to Oahu: 2 to 3 business days standard mail-order; next-day available at local retail.
• Shipping to neighbor islands: add 1 to 2 business days.

A patient on Oahu with a PA-exempt plan could complete a telehealth visit Monday afternoon and pick up Jardiance at a Longs Drugs location Tuesday morning if the electronic prescription routes to a local pharmacy. A patient on Molokai using mail-order could realistically wait 7 to 10 business days from visit to first dose if a PA is required.

For cash-pay patients using the Lilly Insulin Value Program (which applies specifically to insulin) or the Jardiance Savings Card, the pharmacy adjudication happens in real time at the point of sale, which removes the PA delay entirely. Eligible commercially insured patients pay as little as $10 per 30-day supply using the Boehringer Ingelheim/Lilly savings card at participating pharmacies. [16]

Transferring an Existing Jardiance Prescription to Hawaii

Patients relocating to Hawaii or snowbirds spending extended time on the islands can transfer an existing Jardiance prescription from a mainland pharmacy to any Hawaii-licensed pharmacy. Federal law allows a one-time transfer of a non-controlled prescription between pharmacies in different states, provided both pharmacies are licensed and the prescription has remaining refills.

For ongoing management, Hawaii law requires the prescribing provider to be licensed in Hawaii or to practice under a recognized interstate compact or exemption. The Interstate Medical Licensure Compact (IMLC) covers physician licensure across member states, and Hawaii joined the IMLC. [17] Telehealth providers using IMLC credentials can legally maintain a Hawaii patient's Jardiance prescription without requiring the patient to establish care with a separate Hawaii-based clinician.

The Hawaii Nurse Licensure Compact (NLC) similarly allows NPs licensed in compact member states to practice telehealth with Hawaii patients. Patients should confirm that their out-of-state telehealth provider holds either a Hawaii license or a valid compact license before assuming prescriptions will be honored by local pharmacies. [18]

Monitoring After Starting Jardiance in Hawaii

Starting empagliflozin is not a set-and-forget decision. Monitoring protects against the drug's known adverse effects, which include genital mycotic infections (reported in approximately 6.4% of women and 3.1% of men in clinical trials), urinary tract infections, volume depletion, and the rare but serious euglycemic DKA. [4]

The EMPEROR-Preserved trial (N=5,988) showed empagliflozin reduced the primary composite of cardiovascular death or hospitalization for heart failure by 21% in patients with heart failure and preserved ejection fraction (HR 0.79 to 95% CI 0.69 to 0.90, P<0.001), confirming benefit across the ejection fraction spectrum. [19] Monitoring eGFR every 6 months is standard for patients on SGLT2 inhibitors with baseline CKD.

A standard follow-up schedule after initiation:

• 4 to 6 weeks: review symptoms, blood pressure, and any signs of genital or urinary infection.
• 3 months: repeat HbA1c if initiated for diabetes; assess volume status.
• 6 months: repeat eGFR and creatinine.
• Annually: full metabolic panel, HbA1c, urinalysis, and lipid panel.

Telehealth platforms serving Hawaii can coordinate these lab orders through Hawaii-based Quest or LabCorp patient service centers and review results asynchronously, keeping patients on neighbor islands from making unnecessary trips to Honolulu.

The 2024 ADA Standards of Care note: "For patients with type 2 diabetes and CKD, an SGLT2 inhibitor with demonstrated benefit should be used to reduce CKD progression and cardiovascular events." [6] That recommendation applies equally to a patient managed entirely via telehealth in Hilo as to one seeing a nephrologist in Honolulu.